# BridgeBio Pharma, Inc.: Form 8-K, filed Jul 2, 2026

- Company: [BridgeBio Pharma, Inc.](/companies/bbio.md) (CIK 1743881)
- Form: 8-K
- Filed: 2026-07-02
- Accepted by EDGAR: Jul 2, 2026, 16:23 ET
- Period: 2026-07-01
- Accession: 0001140361-26-027445
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1743881/000114036126027445/ef20077282_8k.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1743881/000114036126027445/

## Items reported

- Item 1.01: Entry into a material agreement
- Item 3.02: Unregistered sale of equity
- Item 3.03: Change to security holders’ rights
- Item 5.03: Amendment to articles or bylaws
- Item 7.01: Regulation FD disclosure
- Item 9.01: Financial statements and exhibits

## Sections

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. https://www.sec.gov/Archives/edgar/data/1743881/000114036126027445/ef20077282_8k.htm

Filed Jul 2, 2026.
Source: SEC EDGAR, the filing index for accession 0001140361-26-027445. Last ingested by Listed: Oct 29, 2026, 19:20 ET. No prices; not investment advice.